Capmatinib

Active Ingredient: Capmatinib
Form: Capsule
Brand Name: Tabrecta
Generic Name: Pmatinib
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Tabrecta is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have a MET exon 14 skipping mutation, as confirmed by an FDA-approved test.

Dosage and Administration:
The recommended dose is 400 mg orally twice daily, with or without food. Capsules must be swallowed whole. If a dose is missed or vomiting occurs, follow your physician's instructions regarding dose adjustment.

Common Side Effects:
Respiratory issues, liver or pancreatic dysfunction, peripheral edema, nausea, musculoskeletal pain, fatigue, vomiting, shortness of breath, cough, and loss of appetite.

Storage:
Store below 25°C in a cool, dry place away from light and out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Tabrecta and Capmatinib?
A: Tabrecta is the brand name registered by the original manufacturer. Capmatinib is the name of its active ingredient.

Q: Is the Tabrecta sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic efficacy as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of this generic version reliable?
A: Yes. We work with Ziska Pharmaceuticals, one of the top pharmaceutical manufacturers in Bangladesh. They operate in-house R&D, production, and quality control facilities, and are certified to meet international pharmaceutical manufacturing standards. You can buy with confidence.

Disclaimer:
This information is for reference only. Please consult your physician and refer to the official medication guide and latest clinical research before making any treatment decisions.

Drug Instructions (Package Insert):
Download Link